| NCT ID | NCT02734277 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Condition | Type 1 Diabetes Mellitus |
| Study Type | OBSERVATIONAL |
| Enrollment | 111 participants |
| Start Date | 2016-08-18 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 111 participants in total. It began in 2016-08-18 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.
Eligibility Criteria
Inclusion Criteria: * Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study. * Ability to sign informed consent/assent (as applicable for children). Exclusion Criteria: * Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or * Inability to comply with the study visit schedule and required assessments.
Contact & Investigator
Linda A. DiMeglio, MD, MPH,MA
STUDY CHAIR
Riley Hospital for Children at Indiana University Health
Frequently Asked Questions
Who can join the NCT02734277 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 35 Years, studying Type 1 Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02734277 currently recruiting?
Yes, NCT02734277 is actively recruiting participants. Visit ClinicalTrials.gov or contact National Institute of Allergy and Infectious Diseases (NIAID) to inquire about joining.
Where is the NCT02734277 trial being conducted?
This trial is being conducted at San Francisco, United States, Stanford, United States, Aurora, United States, New Haven, United States and 8 additional locations.
Who is sponsoring the NCT02734277 clinical trial?
NCT02734277 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The principal investigator is Linda A. DiMeglio, MD, MPH,MA at Riley Hospital for Children at Indiana University Health. The trial plans to enroll 111 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.